Faron Pharmaceuticals Oy has announced the issuance of 333,333 warrants to its lender, IPF Fund II SCA, SICAV-FIAR, with a strike price of 1.50 euros. These warrants are part of a restated warrant holder agreement and may be further increased based on agreed adjustment events. The terms and conditions for 750,000 warrants have been approved by the Board of Directors, with the possibility of additional issuances in the future.
As of the announcement date, IPF holds 1,320,343 warrants, representing 1.8% of the current number of shares in the Company. The warrants entitle the holder to subscribe for the same number of shares using the strike price of EUR 1.50 and can be exercised for a period of seven years.
For further information, interested parties can contact Faron Pharmaceuticals directly or reach out to their investor contacts at LifeSci Advisors, ICR Consilium, Cairn Financial Advisers LLP, Peel Hunt LLP, and Sisu Partners Oy, the Certified Adviser on Nasdaq First North.
This announcement provides insight into Faron Pharmaceuticals Oy's recent issuance of warrants to its lender, IPF Fund II SCA, SICAV-FIAR, and outlines the terms and conditions associated with these warrants. It also highlights the potential for further increases in the number of warrants issued and provides contact information for those seeking additional details.